Why the study?
To incorporate findings from recent notable trials and provide concrete, clinically useful recommendations for bleeding risk assessment and optimal antithrombotic strategies in atrial fibrillation patients undergoing PCI or structural heart disease intervention.
What is the optimal antithrombotic therapeutic strategy for atrial fibrillation patients undergoing PCI or structural heart disease intervention?
What is the optimal antithrombotic therapeutic strategy for atrial fibrillation patients undergoing PCI or structural heart disease intervention?
This guideline provides recommendations for antithrombotic management in AF patients undergoing PCI or structural interventions, favoring NOAC plus clopidogrel over warfarin-based triple therapy.
Answers are grounded in this paper and cite their sources.
Supports dual NOAC-clopidogrel as preferred in AF-PCI; confirms prior RCTs and extends evidence into updated guidelines.
The choice of an adequate antithrombotic regimen for atrial fibrillation patients undergoing emergent or elective percutaneous coronary intervention (PCI) should be based on the ischemic event and on the risk of bleeding. Recent randomized controlled trials have consistently demonstrated that dual antithrombotic therapeutic regimens, using non-vitamin K anticoagulants and clopidogrel, are superior to triple or dual therapy with warfarin and aspirin. This report incorporates findings of recent notable studies to provide concrete, clinically useful details and recommendations for bleeding risk assessment and optimal antithrombotic therapeutic strategies after PCI. In addition, we introduce guidelines for antithrombotic management after structural heart disease intervention.
No takes yet. Share an insight, caveat, or question.
Hwang et al. (2019) conducted a review in Atrial fibrillation undergoing percutaneous coronary intervention or structural heart disease intervention. Dual antithrombotic therapy (NOAC and clopidogrel) vs. Triple or dual therapy with warfarin and aspirin was evaluated. Dual antithrombotic therapy using non-vitamin K anticoagulants and clopidogrel is superior to triple or dual therapy with warfarin and aspirin in AF patients undergoing PCI.
Synapse has enriched 10 related papers. Consider them for comparative context: